BIND Therapeutics, Inc., a clinical-stage nanomedicine company developing a targeted and programmable therapeutics called ACCURINS, has announced that the Phase 2 iNSITE1 clinical trial of its lead drug candidate, BIND-014, is ready to move to ... Read more